11.51
0.52 (4.73%)
| Penutupan Terdahulu | 10.99 |
| Buka | 11.22 |
| Jumlah Dagangan | 243,747 |
| Purata Dagangan (3B) | 693,303 |
| Modal Pasaran | 332,097,152 |
| Harga / Jualan (P/S) | 4.56 |
| Harga / Buku (P/B) | 6.23 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 1 Dec 2025 |
| Margin Keuntungan | -149.57% |
| Margin Operasi (TTM) | -164.32% |
| EPS Cair (TTM) | -4.53 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -12.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 231.07% |
| Nisbah Semasa (MRQ) | 5.29 |
| Aliran Tunai Operasi (OCF TTM) | -55.46 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -72.37 M |
| Pulangan Atas Aset (ROA TTM) | -17.33% |
| Pulangan Atas Ekuiti (ROE TTM) | -74.26% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Enanta Pharmaceuticals, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | 2.0 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.70 |
|
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.57% |
| % Dimiliki oleh Institusi | 87.24% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 28.00 (WestPark Capital, 143.27%) | Beli |
| Median | 17.00 (47.70%) | |
| Rendah | 12.00 (Evercore ISI Group, 4.26%) | Beli |
| Purata | 19.00 (65.07%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 10.50 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JP Morgan | 14 Nov 2025 | 17.00 (47.70%) | Beli | 12.06 |
| WestPark Capital | 30 Sep 2025 | 28.00 (143.27%) | Beli | 11.97 |
| Evercore ISI Group | 15 Sep 2025 | 12.00 (4.26%) | Beli | 7.46 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CAPPS KATHLEEN S. | 13.66 | 14.14 | 2,871 | 39,078 |
| KIEFFER TARA LYNN | - | 14.14 | -753 | -10,647 |
| LULY JAY R. | - | 14.14 | -1,885 | -26,654 |
| LUU BRENDAN | - | 14.14 | -498 | -7,042 |
| OR YAT SUN | - | 14.14 | -753 | -10,647 |
| TROUT HARRY R. III | 13.66 | 14.14 | 5,978 | 81,427 |
| Jumlah Keseluruhan Kuantiti Bersih | 4,960 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 65,514 | |||
| Purata Pembelian Keseluruhan ($) | 13.66 | |||
| Purata Jualan Keseluruhan ($) | 14.14 | |||
| Julat Insider ($) | ||||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| TROUT HARRY R. III | Pegawai | 02 Dec 2025 | Jual (-) | 380 | 14.14 | 5,373 |
| CAPPS KATHLEEN S. | Pegawai | 02 Dec 2025 | Jual (-) | 207 | 14.14 | 2,927 |
| LULY JAY R. | Pegawai | 01 Dec 2025 | Dibuang (-) | 1,885 | 14.14 | 26,654 |
| OR YAT SUN | Pegawai | 01 Dec 2025 | Dibuang (-) | 753 | 14.14 | 10,647 |
| KIEFFER TARA LYNN | Pegawai | 01 Dec 2025 | Dibuang (-) | 753 | 14.14 | 10,647 |
| LUU BRENDAN | Pegawai | 01 Dec 2025 | Dibuang (-) | 498 | 14.14 | 7,042 |
| TROUT HARRY R. III | Pegawai | 01 Dec 2025 | Dibuang (-) | 105 | 14.14 | 1,485 |
| CAPPS KATHLEEN S. | Pegawai | 01 Dec 2025 | Dibuang (-) | 85 | 14.14 | 1,202 |
| TROUT HARRY R. III | Pegawai | 25 Nov 2025 | Diperolehi (+) | 6,463 | 13.66 | 88,285 |
| CAPPS KATHLEEN S. | Pegawai | 25 Nov 2025 | Diperolehi (+) | 3,163 | 13.66 | 43,207 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |